BioPharmSignal logoBioPharmSignal

Biotech News

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

Monopar (MNPR)MonoparClinical readout

MNPR (MNPR) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is mnpr.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

MNPRMonopar2026-07-22 12:00 EST

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

ARWRArrowhead Pharmaceuticals2026-08-30 15:30 EST

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

MNPRMonopar2026-08-19 12:00 EST

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

TEVATeva Pharmaceutical Industries2026-09-02 11:03 EST

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

ARWRArrowhead Pharmaceuticals2026-07-22 11:30 EST

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

INBXInhibrx2026-09-08 11:30 EST

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

BMEABiomea Fusion2026-08-24 11:00 EST

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

View all latest news

Monopar

Monopar Therapeutics is a biotechnology company focused on oncology and rare disease, with a history of targeting difficult indications. Its narrative is built around using a concentrated pipeline to create value in high-unmet-need settings.

Recent company news

MNPRMonopar2026-08-19 12:00 EST

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

MNPRMonopar2026-08-12 13:30 EST

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

MNPRMonopar2026-07-22 12:00 EST

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

MNPRMonopar2026-07-20 12:00 EST

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

MNPRMonopar2026-06-30 12:00 EST

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

Stock data

Close
102.70 USD
Market cap
410.38M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States